Abstract

Introduction: Autoantibodies are circulating antibodies generated against self-antigens. In cancer, certain autoantibodies are produced based on cancer antigens that are present on the cancer cells. These antibodies have the potential to become minimally invasive diagnostic and prognostic biomarkers in cancer. In this study, we aim to profile the presence of autoantibodies in the sera of glioblastoma multiforme (GBM) patients. Methods: We obtained 20 serum of ten GBM patients and ten healthy participants from UMBI’s Biobank. We then subjected the profiling of autoantibodies using the i-OME antibody array by Sengenics Malaysia per the manufacturer’s instructions. The slides were scanned using the Agilent Scanner (USA) and the image data was extracted. Data analysis was performed using the Loess normalization and fold change analysis. Results: After the normalization, we performed a cut-off analysis at >1.5 or <-1.5 fold change. With these criteria, we obtained 20 upregulated and 2 downregulated autoantibodies. The topmost upregulated autoantibodies include PDCL3, CRYAB, ENO2, HSP90AA1 and CT47A1. Whereas the two downregulated autoantibodies are ASNA1 and FIP1L1. Conclusion: Based on our analysis, certain antibodies, such as HSP90AA1 and KRT19 have the potential to become minimally invasive biomarkers for GBM as shown by the ROC analysis.

Keywords: Tumor antigens, Brain cancer, Biomarker, Liquid biopsy